Document is current

Article History

Received: 21 May 2021

Accepted: 18 June 2021

First Online: 30 June 2021

Declarations

:

: Not applicable.

: Not applicable.

: Paolo A. Ascierto (PAA): <i>Consulting fee</i>: BMS, Roche, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, Newlinks Genetics, Genmab, Medimmune, Sindax, AstraZeneca, Sun Pharma, Sanofi, Idera, Ultimovacs, Sandox, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Pfizer, Oncosec, Nouscom, Takis, Lunaphore. <i>Contracted Research:</i> BMS, Roche, Array. <i>Travel Support</i>: MSD. Christian Blank (CB): Advisory role: BMS, MSD, Roche, Novartis, GSK, AZ, Pfizer, Lilly, GenMab, Pierre Fabre, Third Rock Ventures—Research funding: BMS, Novartis, NanoString—Stockownership: Uniti Cars, co-founder Immagene BV. Reinhard Dummer (RD): I have intermittent, project-focused consulting and/or advisory relationships with Novartis, Merck Sharp & Dohme (MSD), Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma, Sanofi, and Catalym. Soldano Ferrone (SF): in the past 2 (two) years he has received the funding from Merck. Bernard A. Fox (BAF): Scientific Advisory Board (Advising/Consulting/Stock): Akoya/PerkinElmer, AstraZeneca / MedImmune, Bayer, Bristol-Myers Squibb, CellDex Therapeutics, Definiens, Incyte, Janssen /Johnson & Johnson, Macrogenics, PrimeVax—stock, Turnstone, UbiVac—Co founder/CEO/stock, Ultivue—Research Support: Akoya/PerkinElmer, Bayer, Bristol-Myers Squibb, Definiens, Janssen / Johnson & Johnson, Macrogenics, MedImmune/AstraZeneca, NanoString, OncoSec, Quanterix, Shimadzu, Ventana/Roche, Viralytics/Merck. Claus Garbe (CG): reports personal fees from Amgen, grants and personal fees from BMS, personal fees from MSD, grants and personal fees from Novartis, grants and personal fees from NeraCare, personal fees from Philogen, grants from Roche, grants and personal fees from Sanofi, outside the submitted work. Thomas F. Gajewski (TFG): Advisory boards: Roche-Genentech, Merck, Abbvie, Bayer, Aduro, FogPharma, Adaptimmune. Research support: Roche-Genentech, BMS, Merck, Incyte, Seattle Genetics, Celldex, Ono, Evelo. Cofounder, shareholder: Jounce. Patrick Hwu (PH): Scientific Advisory Board: Immatics US, Inc., Dragonfly, GlaxoSmithKline, Sanofi Pasteur. Roger S. Lo (RSO): Research funding: OncoSec, Novartis, Merck; Research funding-drug-only: Plexxikon; BeiGene; Genentech; Clinical trial funding: Array, BMS; Consultant: Novartis, Array, Amgen, Merck. Jason J. Luke (JJL): Data and Safety Monitoring Board: TTC Oncology; Scientific Advisory Board: 7 Hills, Actym, Alphamab Oncology, Mavu (now part of AbbVie), Pyxis, Springbank, Tempest; Consultancy: Abbvie, Akrevia, Algios, Array, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Compugen, Eisai, EMD Serono, Ideaya, Immunocore, Incyte, Janssen, Leap, Merck, Mersana, Novartis, RefleXion, Silicon, Tesaro, Vividion; Research Support: (all to institution for clinical trials unless noted): AbbVie, Agios (IIT), Array (IIT), Astellas, Boston Biomedical, Bristol-Myers Squibb, CheckMate (SRA), Compugen, Corvus, EMD Serono, Evelo (SRA), Five Prime, FLX Bio, Genentech, Immatics, Immunocore, Incyte, Leap, MedImmune, Macrogenics, Necktar, Novartis, Palleon (SRA), Merck, Springbank, Tesaro, Tizona, Xencor; Travel: Akrevia, AstraZeneca, Bayer, Bristol-Myers Squibb, EMD Serono, Immunocore, Incyte, Janssen, Merck, Mersana, Novartis, RefleXion; Patents: (both provisional) Serial #15/612,657 (Cancer Immunotherapy), PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof). Michelle Kroogsgard (MK): Merck Sharp & Dohme, Agenus Inc. Michael A. Postow (MAP): Consulting fees: BMS, Merck, Array BioPharma, Novartis, Incyte, NewLink Genetics, Aduro, Eisai, Pfizer—Honoraria: BMS and Merck—Institutional Support: RGenix, Infinity, BMS, Merck, Array BioPharma, Novartis, AstraZeneca. Michele W.L. Teng (MWLT): Received consultancy honoraria from Trishula Therapeutics—Received speaker’s honorarium and/or travel support from BMS MSD, Novartis. Alessandro Testori (AT): declares he has not conflict of interest related to the topics in this paper; received travel support for meetings from Agenus. Igor Puzanov (IP): Amgen-consultant fees, steering committee member KEYNOTE 265; Merck-advisory board fees; Sotio-consultant fees; Celldex-private stock ownership. <i>Institutional Clinical Trial Support:</i> Nektar, Idera, Oncosec, Amgen, Rgenix, Immunocore, Dynavax. Marc S. Ernstoff (MSE); Pawel Kalinski (PK); Bart Neyns (BN); Sergio A. Quezada (SAQ); Giorgio Trinchieri (GT), Corrado Caracò (CC), Iman Osman (IO), Magdalena Thurin (MT): nothing to declare.